

PART VI- Summary of the risk management plan

Summary of risk management plan for Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti.

This is a summary of the risk management plan (RMP) for Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti.

The RMP details important risks of Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti, how these risks can be minimised, and how more information will be obtained about Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti ´s risks and uncertainties (missing information).

Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti ´s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti should be used.

Important new concerns or changes to the current ones will be included in updates of Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti ´s RMP.

I. The medicine and what it is used for

Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti is authorised and indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale: EDSS 4-7). (see SmPC for the full indication).

It contains fampridine as the active substance, and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti . Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 1. Summary of Safety Concerns

Important Identified Risks	None
Important Potential Risks	None

Missing Information	None
---------------------	------

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Fampridine Sandoz 10 mg depottablett, Fampridin Medical Valley 10 mg depottabletti, Fampridine Laboratorios Liconsa 10 mg depottabletti, Fampridine Biomo 10 mg depottabletti, Fampridin Zentiva 10 mg Depottabletti .